Johnson & Johnson reports new real-world head-to-head data showing ERLEADA (apalutamide) reduced the risk of death by 51% versus darolutamide in metastatic castration-sensitive prostate cancer patients treated without docetaxel.
Written By: Pharmacally Medical News Desk
Johnson & Johnson has announced new real-world evidence suggesting that ERLEADA® (apalutamide) may provide a meaningful overall survival advantage over darolutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated without docetaxel. The findings were selected as a top abstract and are being presented at the 36th Annual International Prostate Cancer Update on February 2, highlighting outcomes from routine U.S. clinical practice.
In this retrospective head-to-head analysis, patients initiating ERLEADA without docetaxel experienced a statistically significant 51% reduction in the risk of death compared with those initiating darolutamide without docetaxel through 24 months of follow-up. The reported hazard ratio was 0.49 (95% CI, 0.30–0.83; P=0.007), supporting a potential survival advantage for apalutamide in this treatment setting.
The study was designed to meet FDA guidance for real-world evidence generation, incorporating a pre-specified protocol, overall survival as the primary endpoint, power calculations, and propensity score-based adjustment using inverse probability of treatment weighting. Investigators identified 1,460 ERLEADA initiators and 287 darolutamide initiators who began therapy between August 2022 and June 2025, with statistical methods applied to balance baseline differences between groups.
Mehmet Bilen, Director of the Genitourinary Medical Oncology Program at Emory University noted that such analyses can help inform treatment decisions in the absence of prospective head-to-head trials, which are often difficult to conduct in this setting.
Mahadi Baig, Vice President, U.S. Medical Affairs, Johnson & Johnson Innovative Medicine also emphasized that repeated real-world evaluations have continued to show an overall survival benefit for apalutamide compared with other commonly used agents in advanced prostate cancer.
These real-world findings build upon evidence from the pivotal Phase 3 TITAN trial (NCT02489318), where ERLEADA plus androgen deprivation therapy (ADT) demonstrated a statistically significant improvement in overall survival compared with ADT alone. TITAN reported an HR of 0.67 at the primary analysis after a median 22.7 months of follow-up and an HR of 0.65 at the final analysis after a median 44 months. The proportion of patients alive at 24 months in this real-world ERLEADA cohort was broadly consistent with outcomes reported in TITAN, reinforcing the established survival benefit of apalutamide.
As with all observational research, investigators acknowledged potential limitations including miscoding, missing information, and residual confounding. However, the data sources were considered appropriate for identifying the patient population and evaluating survival outcomes, supported by robust statistical weighting techniques intended to replicate trial-like comparability.
Prostate cancer remains a major public health burden in the United States, with approximately 330,000 new diagnoses each year and over 36,000 deaths projected in 2026. A substantial proportion of patients are classified as high-risk, underscoring the importance of selecting effective therapy early in the metastatic disease course.
ERLEADA is an androgen receptor inhibitor approved for both non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Since its FDA approvals in 2018 and 2019, more than 325,000 patients worldwide have been treated with apalutamide, and ongoing Phase 3 trials such as ATLAS (NCT02531516) and PROTEUS (NCT03767244) continue to explore its broader role in prostate cancer management.
For full prescribing details, including information on adverse reactions, warnings, precautions, and contraindications, the ERLEADA prescribing information is available here: CLICK HERE
References
Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months, 02 February 2026, Real-world head-to-head analysis shows 51% reduction in risk of death for patients with metastatic castration-sensitive prostate cancer treated with ERLEADA® (apalutamide) versus darolutamide without docetaxel through 24 months